Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.4% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

2 recruiting

Enrollment Performance

Analytics

N/A
3(75.0%)
Phase 2
1(25.0%)
4Total
N/A(3)
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT07623902Not ApplicableRecruiting

Evaluation of Gixam's Efficacy Predicting the Presence of Advanced and Non-advanced Colorectal Neoplasia in a FIT Negative Population

Role: lead

NCT06305364Not ApplicableCompleted

Predicting Adenomatous Polyps in the Colon Using Images of a Human Tongue

Role: lead

NCT06688110Not ApplicableNot Yet Recruiting

Evaluation of Gixam's Efficacy Predicting Pre-cancerous Colorectal Polyps and Colorectal Cancer

Role: lead

NCT06612281Phase 2Recruiting

Evaluation of Gixam's Performance in a FIT Negative Population

Role: lead

All 4 trials loaded